on INVENTIVA (EPA:IVA)
Inventiva Halts Trading of Ordinary Shares on Euronext Paris
Inventiva, a clinical-stage biopharmaceutical company, announced a temporary halt of its ordinary shares' trading on Euronext Paris. This suspension, requested by the company, is in anticipation of a proposed financing transaction. Details regarding this transaction will be released in a subsequent communication from the company. Trading on Euronext Paris is expected to resume on June 2, 2026, around 3:30 p.m. CEST, coinciding with the earliest expected trading time on the Nasdaq Global Market in the United States under the ticker "IVA."
The company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH) and is currently advancing its clinical trial for lanifibranor.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news